GlyTherix
Manufacturing · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
75 Talavera Rd Ground Fl Ste 2, Macquari...Phone Number
+61 298504000Website
www.glytherix.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About GlyTherix
GlyTherix is an immuno-oncology company focused on developing cancer therapeutics, particularly targeted radiotherapy for solid tumors. The company boasts a comprehensive intellectual property portfolio and has successfully completed a First-in-Human trial for its patented antibody, Miltuximab, which targets the glypican-1 protein overexpressed in various cancers. GlyTherix aims to improve patient outcomes through innovative imaging and treatment solutions, and is currently advancing its research and development efforts in collaboration with leading institutions. Their intended clients include cancer patients and healthcare providers seeking advanced therapeutic options.Explore more
GlyTherix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GlyTherix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at GlyTherix
Product Launch: Get notified when GlyTherix launches new products
Website visits: Recent activity has been detected on your website
GlyTherix, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if GlyTherix is spiking on competitors!
Click to see if GlyTherix had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once GlyTherix has new funding data
Earning: See what the market has to say on GlyTherix recently announced quarterly report
Check if GlyTherix has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to GlyTherix
Compare insights from companies similar to GlyTherix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
GlyTherix is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
GlyTherix is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about GlyTherix.
GlyTherix Tech Stack
A closer look at the technologies used by GlyTherix
See more technologies
GlyTherix News & Media
Nusano and GlyTherix Announce Lutetium-177 Supply Agreement
VALENCIA, Calif. and SYDNEY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specializing in developing antibody radiopharmaceuticals for solid tumors, today announced a supply agreement for non-carrier-added lutetium-177 (Lu-177). The agreement also provides GlyTherix access to Nusano’s future actinium-225 (Ac-225) production, currently scheduled to begin in 2026,GlyTherix to Partner with SHINE Technologies for Advancing Targeted Radiotherapy in Aggressive Cancers
JANESVILLE, Wis., Sept. 18, 2024 /PRNewswire/ -- GlyTherix Ltd (GlyTherix) an Australian targeted radiotherapy company specializing in developing antibody radiopharmaceuticals for solid tumors today is pleased to announce a new global clinical supply agreement with Wisconsin-based SHINE...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding GlyTherix
Sign Up For FreeTo access detailed company insights
GlyTherix is an immuno-oncology company focused on developing cancer therapeutics, particularly targeted radiotherapy for solid tumors. The company boasts a comprehensive intellectual property portfolio and has successfully completed a First-in-Human trial for its patented antibody, Miltuximab, which targets the glypican-1 protein overexpressed in... Read More
